[Skip to Content]
[Skip to Content Landing]
Article
June 1960

Diphenyl Thiourea Derivative in the Therapy of Rosacea

Author Affiliations

Cincinnati

From The Department of Dermatology of the College of Medicine of the University of Cincinnati.

AMA Arch Derm. 1960;81(6):971. doi:10.1001/archderm.1960.03730060087018
Abstract

At the VII International Congress of Leprology in Tokyo, Mayer and Davey1 reported on the diphenyl thiourea compounds in regard to their antituberculosis and antileprosy activity. This compound, known as SU 1906, or DPT, is a substituted thiocarbanilide, 4-butoxy-4′di-methyl-amino-diphenyl thiourea, which has been studied now for over four years in the treatment of leprosy. The most extensive work was done by Davey2 of the Uzuakoli Research Centre in Nigeria, West Africa. One of the important properties of this material was its freedom from toxicity.

Because of the interest of the dermatologist in drugs used in the treatment of Hansen's disease, it was decided to use this nontoxic compound in the study of various dermatoses. Because of the presence of a thio compound, rosacea was the first dermatosis selected. It is admittedly difficult to assay the value of any oral therapy in rosacea, so 56 patients with severe rosacea

×